Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

American Regent Venofer Injectable Iron Approval Expected In Third Quarter

Executive Summary

American Regent Labs expects FDA approval of the injectable iron product Venofer during the third quarter of 2000.

You may also be interested in...



Watson Ferrlecit

Sodium ferric gluconate injection covered by Medicare as of Dec. 1 as a first-line treatment of iron deficiency anemia in patients undergoing chronic hemodialysis who are receiving supplemental EPO therapy. HCFA issued a National Coverage Decision for the agent on April 20 (1"The Pink Sheet" May 22, p. 25)

Watson Ferrlecit

Sodium ferric gluconate injection covered by Medicare as of Dec. 1 as a first-line treatment of iron deficiency anemia in patients undergoing chronic hemodialysis who are receiving supplemental EPO therapy. HCFA issued a National Coverage Decision for the agent on April 20 (1"The Pink Sheet" May 22, p. 25)

Watson To Acquire Schein: Generic Business Projected At $800 Mil. In 2001

Watson expects its generic drug business to top $800 mil. in revenues during 2001 after it completes the proposed acquisition of Schein.

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel